The Food and Drug Administration, in clearing the first direct-to-consumer genetic test for disease risk, is signaling that it will allow a wide range of certain genetic tests onto the U.S. market without FDA review.
via WSJ.com: US Business http://ift.tt/17C6Va3
via WSJ.com: US Business http://ift.tt/17C6Va3
Nessun commento:
Posta un commento